1. |
Cancer prevention inBRCA1mutation carriers |
|
Inpharma Weekly,
Volume &NA;,
Issue 1358,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1358,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1358,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Strict guidelines for prescription drug use mean millions in savings |
|
Inpharma Weekly,
Volume &NA;,
Issue 1358,
2002,
Page 5-6
Cameron Johnston,
Preview
|
|
摘要:
The increasing cost of prescription drugs is creating a profound economic challenge for governments that provide publicly-funded drug reimbursement programmes. However, the Canadian province of British Columbia (population 3.9 million) has documented, in a rigorous economic analysis, savings amounting to several million dollars per year by implementing guidelines recommending which patients may be eligible to receive certain drugs, and setting a ceiling on the amounts that will be reimbursed to patients for other drugs.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Paclitaxel confers QOL benefit, lower costs in breast cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1358,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1358,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1358,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News from TCT symposium ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1358,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1358,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Ziprasidone shows advantages in schizophrenia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1358,
2002,
Page 11-13
Raewyn Poole,
Preview
|
|
摘要:
The atypical antipsychotic ziprasidone ['Geodon'] is an effective and well tolerated therapy for schizophrenia, according to studies presented at the XII World Congress of Psychiatry [Yokohama, Japan; August 2002]. In one study, ziprasidone and olanzapine ['Zyprexa'] provided comparable improvements in psychopathology, global illness severity, and cognitive function in patients with schizophrenia. A second study showed that ziprasidone was as effective as the conventional antipsychotic haloperidol ['Haldol'] in the treatment of acute schizophrenia, although IM ziprasidone provided more rapid improvement in some measures. Ziprasidone demonstrated favourable tolerability profiles in these studies; ziprasidone was less likely than olanzapine to adversely affect bodyweight or metabolic parameters, and the incidence of movement disorders was significantly lower in ziprasidone, compared with haloperidol, recipients. Switching to ziprasidone was shown to provide further improvement of symptoms in patients previously treated with conventional antipsychotics, olanzapine or risperidone ['Risperdal'], according to an analysis of data from three studies.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|